Emerging evidence suggests a link between circulating PRL levels and increased breast cancer risk in ER+/progesterone receptor-positive (PR+) patients; however, the prevailing paradigm attributes PRL's oncogenic effects predominantly to local autocrine/paracrine actions rather than systemic endocrine mechanisms. The gene discussed is ESR1; the disease is breast cancer.